Anti-GP41 antibody-specific capture agents, compositions, and methods of using and making

Patent metadata

Field	Value
Publication number	US-10597425-B2
Application number	US-201414484610-A
Country	US
Kind code	B2
Filing date	Sep 12, 2014
Priority date	Sep 12, 2013
Publication date	Mar 24, 2020
Grant date	Mar 24, 2020

Abstract

The present application provides stable peptide-based anti-gp41 antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing anti-gp41 antibody capture agents using iterative on-bead in situ click chemistry.

First claim

What is claimed is:

1. A synthetic capture agent produced by steps comprising
(a) providing:
(i) an antibody of interest, wherein the antibody of interest is specific for an epitope,
(ii) a compound comprising a peptide corresponding to the epitope and an azido group or an alkynyl group, and
(iii) a library of candidate peptides, wherein the candidate peptides each comprise an amino acid sequence comprising the formula X 1 -X 2 -X 3 -X 4 -X 5 , wherein X 1 , X 2 , X 3 , X 4 and X 5 , each represent glycine or a D-amino acid other than cysteine and methionine, wherein the candidate peptides each further comprise an azido group if the compound comprises an alkynyl group or an alkynyl group if the compound comprises an azido group; and

(b) contacting the antibody of interest, the compound, and the library of candidate peptides, whereby a disubstituted 1,2,3-triazole linkage is formed between the compound and one of the candidate peptides when the azido group and alkynyl group of the compound and one of the candidate peptides are brought in close proximity upon binding to the antibody of interest, whereby the candidate peptide linked to the compound is identified as the candidate peptide to be used in the capture agent,
wherein:
(i) the capture agent is the linked candidate peptide and compound formed in step (b) or
(ii) the capture agent is formed by covalently linking together a separate instance of the peptide of the compound and a separate instance of the candidate peptide identified in step (b), thereby producing the capture agent, wherein the peptide of the compound and identified candidate peptide are linked together via a 1,4-substituted-1,2,3-triazole residue (Tz4) or via a 1,5-substituted-1,2,3-triazole residue (Tz5), wherein the capture agent specifically binds the antibody of interest.

2. The capture agent of claim 1 , wherein the capture agent is labeled with a label selected from the group consisting of biotin, copper-DOTA, biotin-PEG3, aminooxyacetate, 19 FB, 18 FB and FITC-PEG3.

3. The capture agent of claim 1 , wherein the capture agent is labeled with the detectable moiety selected from the group consisting of 64 Cu DOTA, 68 Ga DOTA, 68 Ga NOTA, 18 F, Al 18 F NOTA, 64 Cu, 68 Ga, 89 Zr, 124 I, 86 Y, 94m Tc, 110m In, 11 C and 76 Br.

4. A synthetic capture agent, wherein the capture agent specifically binds an anti-gp41 antibody,
wherein the capture agent has the structure:

5. A composition comprising two or more capture agents of claim 1 .

6. The synthetic capture agent of claim 1 ,
wherein the antibody of interest is an anti-gp41 antibody,
wherein the peptide of the compound comprises the amino acid sequence of IWCGSGKLICTTA (SEQ ID NO: 1),
wherein the identified candidate peptide comprises the amino acid sequence selected from the group consisting of dkGlp (SEQ ID NO: 8); vadpa (SEQ ID NO: 9); nidnG (SEQ ID NO: 2); pGvtf (SEQ ID NO: 10); srrrs (SEQ ID NO: 11); dq/eGaf (SEQ ID NO: 12); ywdyn (SEQ ID NO: 13); hllyq (SEQ ID NO: 14); sGaqs (SEQ ID NO: 15); ddwai (SEQ ID NO: 16); qidlr (SEQ ID NO: 17); tfLqs (SEQ ID NO: 18); hnpfk (SEQ ID NO: 3); wGehp (SEQ ID NO: 19); qndwK (SEQ ID NO: 20); ItsrY (SEQ ID NO: 21); diksp (SEQ ID NO: 22); eihny (SEQ ID NO: 4); qpidq (SEQ ID NO: 23); kidrv (SEQ ID NO: 24); qsp/dwl (SEQ ID NO: 25); and eqtfd (SEQ ID NO: 26).

7. The capture agent of claim 1 , wherein the antibody of interest is an anti-gp41 antibody.

8. The synthetic capture agent of claim 1 , wherein the capture agent specifically binds an anti-gp41 antibody, wherein the peptide of the compound comprises an amino acid sequence 80 to 100% identical to IWCGSGKLICTTA (SEQ ID NO: 1), wherein the identified candidate peptide comprises an amino acid sequence 80 to 100% identical to an amino acid sequence selected from the group consisting of dkGlp (SEQ ID NO: 8); vadpa (SEQ ID NO: 9); nidnG (SEQ ID NO: 2); pGvtf (SEQ ID NO: 10); srrrs (SEQ ID NO: 11); dq/eGaf (SEQ ID NO: 12); ywdyn (SEQ ID NO: 13); hllyq (SEQ ID NO: 14); sGaqs (SEQ ID NO: 15); ddwai (SEQ ID NO: 16); qidlr (SEQ ID NO: 17); tfLqs (SEQ ID NO: 18); hnpfk (SEQ ID NO: 3); wGehp (SEQ ID NO: 19); qndwK (SEQ ID NO: 20); ItsrY (SEQ ID NO: 21); diksp (SEQ ID NO: 22); eihny (SEQ ID NO: 4); qpidq (SEQ ID NO: 23); kidrv (SEQ ID NO: 24); qsp/dwl (SEQ ID NO: 25); and eqtfd (SEQ ID NO: 26).

9. The synthetic capture agent of claim 1 ,
wherein the peptide of the compound comprises the amino acid sequence IWCGSGKLICTTA (SEQ ID NO: 1), wherein the identified candidate peptide comprises an amino acid sequence selected from the group consisting of dkGlp (SEQ ID NO: 8); vadpa (SEQ ID NO: 9); nidnG (SEQ ID NO: 2); pGvtf (SEQ ID NO: 10); srrrs (SEQ ID NO: 11); dq/eGaf (SEQ ID NO: 12); ywdyn (SEQ ID NO: 13); hllyq (SEQ ID NO: 14); sGaqs (SEQ ID NO: 15); ddwai (SEQ ID NO: 16); qidlr (SEQ ID NO: 17); tfLqs (SEQ ID NO: 18); hnpfk (SEQ ID NO: 3); wGehp (SEQ ID NO: 19); qndwK (SEQ ID NO: 20); ItsrY (SEQ ID NO: 21); diksp (SEQ ID NO: 22); eihny (SEQ ID NO: 4); qpidq (SEQ ID NO: 23); kidrv (SEQ ID NO: 24); qsp/dwl (SEQ ID NO: 25); and eqtfd (SEQ ID NO: 26).

10. The capture agent of claim 9 , wherein the identified candidate peptide comprises an amino acid sequence selected from the group consisting of nidnG (SEQ ID NO: 2), hnpfk (SEQ ID NO: 3) and eihny (SEQ ID NO: 4).

11. The capture agent of claim 10 , wherein the identified candidate peptide comprises the amino acid sequence nidnG (SEQ ID NO: 2).

12. The capture agent of claim 10 , wherein the identified candidate peptide comprises the amino acid sequence hnpfk (SEQ ID NO: 3).

13. The capture agent of claim 10 , wherein the identified candidate peptide comprises the amino acid sequence eihny (SEQ ID NO: 4).

14. The capture agent of claim 8 , wherein the capture agent is labeled with a label selected from the group consisting of biotin, copper-DOTA, biotin-PEG3, aminooxyacetate, 19 FB, 18 FB and FITC-PEG3.

15. The capture agent of claim 8 , wherein the capture agent is labeled with the detectable moiety selected from the group consisting of 64 Cu DOTA, 68 Ga DOTA, 68 Ga NOTA, 18 F, Al 18 F NOTA, 64 Cu, 68 Ga, 89 Zr, 124 I, 86 Y, 94m Tc, 110m In, 11 C and 76 Br.

16. The capture agent of claim 7 , wherein the peptide of the compound comprises an amino acid sequence 80 to 100% identical to IWCGSGKLICTTA (SEQ ID NO: 1).

17. The capture agent of claim 16 , wherein the identified candidate peptide comprises an amino acid sequence 80 to 100% identical to an amino acid sequence selected from the group consisting of dkGlp (SEQ ID NO: 8); vadpa (SEQ ID NO: 9); nidnG (SEQ ID NO: 2); pGvtf (SEQ ID NO: 10); srrrs (SEQ ID NO: 11); dq/eGaf (SEQ ID NO: 12); ywdyn (SEQ ID NO: 13); hllyq (SEQ ID NO: 14); sGaqs (SEQ ID NO: 15); ddwai (SEQ ID NO: 16); qidlr (SEQ ID NO: 17); tfLqs (SEQ ID NO: 18); hnpfk (SEQ ID NO: 3); wGehp (SEQ ID NO: 19); qndwK (SEQ ID NO: 20); ItsrY (SEQ ID NO: 21); diksp (SEQ ID NO: 22); eihny (SEQ ID NO: 4); qpidq (SEQ ID NO: 23); kidrv (SEQ ID NO: 24); qsp/dwl (SEQ ID NO: 25); and eqtfd (SEQ ID NO: 26).

18. The capture agent of claim 6 , wherein the identified candidate peptide comprises an amino acid sequence selected from the group consisting of nidnG (SEQ ID NO: 2), hnpfk (SEQ ID NO: 3) and eihny (SEQ ID NO: 4).

19. The capture agent of claim 18 , wherein the identified candidate peptide comprises the amino acid sequence of nidnG (SEQ ID NO: 2).

20. The capture agent of claim 18 , wherein t

Assignees

• California Inst Of Techn

Inventors

• Pfeilsticker Jessica A
• Umeda Aiko
• Heath James R

Classifications

• G01N2333/162

  env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site · CPC title

• C07K9/00 Primary

  Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof · CPC title

• G01N33/56988

  HIV or HTLV · CPC title

• G01N2469/20

  Detection of antibodies in sample from host which are directed against antigens from microorganisms · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title